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This review describes the current knowledge regarding genetics and epigenetics of
pregnancy-associated diseases with placental origin. We discuss the effect on genetic
linkage analyses when the fetal genotype determines the maternal phenotype. Secondly,
the genes identiﬁed by genome-wide linkage studies to be associated with pre-eclampsia
(ACVR2A, STOX1) and the HELLP-syndrome (LINC-HELLP ) are discussed regarding their
potential functions in the etiology of disease. Furthermore, susceptibility genes identiﬁed
by candidate gene approaches (e.g., CORIN ) are described. Next, we focus on the
additional challenges that come when epigenetics also play a role in disease inheritance.
We discuss the maternal transmission of the chromosome 10q22 pre-eclampsia linkage
region containing the STOX1 gene and provide further evidence for the role of epigenetics
in pre-eclampsia based on the cdkn1c mouse model of pre-eclampsia. Finally, we provide
recommendations to unravel the genetics of pregnancy-associated diseases, speciﬁcally
regarding clear deﬁnitions of patient groups and sufﬁcient patient numbers, and the
potential usefulness of (epi)genetic data in early non-invasive biomarker development.
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INTRODUCTION
This review will describe the current status of the genetics and
epigenetics behind pregnancy-associated diseases with placental
origin. It focuses especially on the manner of inheritance of these
maternal diseases that originate in the fetal placenta as this compli-
cates genome-wide association studies. The second focus centers
on the additional challenges that come into play when epigenetics
are also involved in the inheritance of disease.
Pregnancy-induced hypertension, pre-eclampsia, eclampsia
and the HELLP syndrome are all diseases that occur during
pregnancy giving symptoms in the mother from 20 weeks of
gestation onward. Next to pregnancy-induced hypertension also
pre-eclampsia is characterized by hypertension occurring simul-
taneously with proteinuria. In eclampsia patients suffer from
seizures, while in the HELLP syndrome the symptoms consist of
haemolysis, elevated liver enzymes and lowplatelet count (Steegers
et al., 2010). Complete clinical characteristics including the occur-
rence percentages can be found in Table 1. The only cure currently
available for all of these diseases is removal of the placenta and
thus delivery of the baby.
The pregnancy-associated diseases with placental origin are
seen both separately and in combination, e.g., eclampsia and
the HELLP syndrome are often superimposed on pre-eclampsia.
However, it gets more widely acknowledged that the diseases are
different entities. Furthermore, it is important to stress that a
differentiation is required between early- and late-onset of dis-
ease, where early-onset is deﬁned as the occurrence of clinical
symptoms before 34 weeks. Early-onset is furthermore character-
ized by a high risk of fetal and maternal morbidity and mortality,
an abnormal placental morphology, a clear familial component
and association with intra-uterine growth restriction (deﬁned as a
decrease in fetal growth rate that prevents an infant fromobtaining
its complete growth potential). On the other hand, late-onset dis-
ease shows normal placental morphology, but is characterized
by many maternal risk factors such as diabetes, cardiovascular
disorders, increased body mass index (BMI), etc (Steegers et al.,
2010).
GENETICS OF PRE-ECLAMPSIA AND THE HELLP SYNDROME
FETAL GENOTYPE DETERMINES MATERNAL PHENOTYPE
Most (genetic) research investigating pregnancy-associated dis-
eases is performedon the early-onset formsof disease. These forms
not only have the highest morbidity and mortality risk for both
mother and child, but, as these forms run in families, also have a
genetic component (Laivuori, 2007). The consistent observations
that the early-onset form shows an abnormal placental morphol-
ogy and is often associated with intra-uterine growth restriction
indicate that early-onset disease originates in the fetal placenta
(Roberts and Hubel, 2009). During a healthy pregnancy, the fetal-
maternal interface is formed in the ﬁrst trimester of pregnancy
when extravillous trophoblasts from the fetal placenta invade into
the maternal decidua up to one-third of the myometrium. By
invading the maternal decidua, the maternal spiral arteries located
within the decidua are remodeled, transforming them from low-
capacity high-resistance into high-capacity low-resistance vessels,
by replacing smooth muscle and elastic tissue with ﬁbrinoid
material (James et al., 2010).
In early-onset pregnancy-associated disease a reduction in fetal
trophoblast invasion is observed together with reduced spiral
artery remodeling. This in turn decreases the blood ﬂow toward
the placenta reducing the oxygen and nutrient transfer to the fetus.
To compensate, themother increases her blood pressure, at the end
of the second and in third trimester leading to the symptoms as
described above (James et al., 2010).
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Table 1 | Clinical subtypes of pregnancy-induced hypertension.
Disease Clinical symptoms* Occurrence#
Pregnancy-induced
hypertension
Blood pressure >140/90 6–8%
Pre-eclampsia Blood pressure >140/90 5–8%
Proteinuria >300 mg/24 h
Eclampsia Blood pressure >140/90 0.05%
Tonic-clonic seizures
HELLP syndrome LD > 600 IU/l 0.5–1%
ASAT > 70 IU/l
ALAT > 70 IU/l
Platelets <100 × 109/l
*Steegers et al., 2010
#World Health Organisation (2005),Wallis et al., 2008, Duley (2009), Haram et al.,
2009.
As early-onset disease originates in the fetal placenta it must be
concluded that the fetal genotype of the placental trophoblasts is
(partially) able to determine the maternal disease phenotype. If
pre-eclampsia is considered to be an autosomal recessive disease,
the father and mother are genetic carriers and their unborn child
with its placenta is genetically affected, leading to the phenotypic
disease in the mother. Further evidence for the placental origin of
early-onset pre-eclampsia comes from the consistent observation
that parous monozygotic twins are discordant for pre-eclampsia
(Treloar et al., 2001).
It is now widely accepted that pre-eclampsia is a multi-factorial
disease in which both maternal and fetoplacental factors are con-
tributing; different combinations of factors will lead to differences
in time of onset, disease severity, etc. Some of these factors will
be hereditary leading to the familial components seen in early-
onset pregnancy-associated diseases. The ﬁrst step in identifying
the fetal and maternal causal factors is to subcategorize the disease
to yield homogenous patient populations. Secondly, when per-
forming research on genetic linkage in familial early-onset disease
originating in the placenta, the study should focus on the placen-
tal genotype rather than the maternal genotype. This implies it is
a necessity to have samples from both the mother and the child
born out of the affected pregnancy. Another option is to consider
an affected mother born from an unaffected mother carrier, while
affected mothers born from affected pregnancies themselves can
be considered cases.
SUSCEPTIBILITY GENES IN PRE-ECLAMPSIA
To identify genes involved in pre-eclampsia multiple genetic
screens (genome-wide scans, variance-components linkage analy-
sis, association analysis) have been performed in multiple patient
populations (families, case-control; Arngrímsson et al., 1999;
Moses et al., 2000; Lachmeijer et al., 2001; Laasanen et al., 2003;
Laivuori et al., 2003; Fitzpatrick et al., 2004; Oudejans et al., 2004;
Johnson et al., 2007). This has so far yielded limited results with
only two susceptibility genes (ACVR2A and STOX1) identiﬁed
(VanDijk et al., 2005; Moses et al., 2006), within conﬁrmed regions
with signiﬁcant genome-wide linkage. For both susceptibility
genes the alleles associated involve normal variations (SNPs:
single nucleotide polymorphisms) consistent with the common
variant-common disease hypothesis (Wang et al., 2005). Fur-
thermore, both were originally identiﬁed in familial forms of
pre-eclampsia.
ACVR2A
ACVR2A is located on chromosome 2q22 and was originally iden-
tiﬁed in an Australian/New Zealand population of pre-eclamptic
pedigrees (Moses et al., 2006). This linkage was subsequently con-
ﬁrmed in a Norwegian case-control study (Roten et al., 2009),
although later studies in a subset of the Australian population
(Fitzpatrick et al., 2009) as well as a Finnish population (Lokki
et al., 2011) were unable to identify signiﬁcant linkage. The
ACVR2A gene codes for an Activin receptor type II that is able
to bind Activin ligands. Activin A has a role on both the maternal
and the fetal site of the placenta, where on the maternal site it pro-
motes decidualization of endometrial stromal cells and regulates
trophoblast invasion into the decidua (Jones et al., 2002), while
on the fetal site it promotes trophoblast differentiation (Caniggia
et al., 1997). Furthermore, multiple studies have found increased
Activin A levels in serum of pre-eclamptic women (Giguère et al.,
2010). None of the SNPs identiﬁed byACVR2A linkage are located
in exons. They therefore might not appear to be relevant in the
etiology of pre-eclampsia, but they are potentially located in areas
controlling ACVR2A transcription or regulation. For instance, if
the SNP is located within the promoter region of ACVR2A it can
affect the binding of transcription factors regulating transcription
of the gene or, when the SNP for example is located within a
microRNA binding site, it might affect the binding of microRNAs
causing a change in the amount of ACVR2A mRNA available for
translation into protein.
STOX1
STOX1 was originally identiﬁed in a Dutch population consist-
ing of affected siblings and their relatives, in which the affected
women showed familial severe early-onset pre-eclampsia com-
plicated by IUGR (intra uterine growth restriction). The coding
linkage regions on chromosome 10q22 were sequenced identify-
ing a common polymorphism in STOX1, Y153H, with maternal
transmission in three generations (Van Dijk et al., 2005). Link-
age of this gene to pre-eclampsia has also been difﬁcult to
replicate in other population cohorts (Iglesias-Platas et al., 2007;
Kivinen et al., 2007). This is mainly due to unclearly deﬁned
disease characteristics of the pre-eclamptic women; the popula-
tions consisted of a combination of mild and severe, early- and
late-onset pre-eclampsia, and the disease did not always show
familial inheritance. Furthermore, as the replication studies were
performed on maternal genotypes, this implies another method
needs to be used for linkage data analysis to correct for the
fetal genotype determining the maternal phenotype as described
above. One study, also performed in a Dutch population, did take
both criteria, i.e., a homogenous patient population and familial
inheritance enabling to correct for the fetal genotype determin-
ing the maternal phenotype, into account; using a homogenous
patient population and three generations with a grandmaternal
origin of the disease, a signiﬁcant maternal transmission of the
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STOX1 Y153H allele was found (Berends et al., 2007). A study
in a Norwegian population could not ﬁnd a signiﬁcant trans-
mission of the pre-eclampsia susceptibility H-allele, but, when
analyzing recurrent pre-eclampsia patients only (where disease
recurrence is indicative of genetic origin), a trend toward sig-
niﬁcance of maternal transmission was detected (Fenstad et al.,
2010).
The STOX1 gene codes for a protein containing a winged helix
domain, indicating that it acts as a transcription factor (Van Dijk
et al., 2005). The Y153H SNP is located within the DNA binding
winged helix domain and the H-allele, the allele associated with
pre-eclampsia, has been found to have a higher binding afﬁnity for
CTNNA3, a gene transcribed by binding of STOX1 (Van Dijk et al.,
2010). CTNNA3, coding for αT-catenin, is a component of the
cell–cell adhesion complex (Janssens et al., 2001). Upregulation of
αT-catenin causes a reduction in invasion capacity of trophoblasts
(Tyberghein et al., 2012),while proliferation is promoted (VanDijk
et al., 2010). First trimester placental explants homozygous for the
STOX1H-allele showed reduced trophoblast invasion and induced
responsiveness of CTNNA3 expression upon STOX1 expression
(Van Dijk et al., 2010). This genotype, STOX1 Y153H, therefore
has a demonstrated effect on trophoblast invasion, central in the
etiology of early-onset pre-eclampsia.
By overexpressing STOX1 in human choriocarcinoma cells
transcriptomic alterations were induced that resembled those
seen in pre-eclamptic placentas (Rigourd et al., 2008). Recently,
this group developed transgenic mouse strains overexpressing
human STOX1 (Doridot et al., 2013). Wildtype female mice
crossed with transgenic male mice developed severe pre-eclamptic
symptoms, i.e., gestational hypertension and proteinuria. Fur-
thermore, the placenta and kidney morphologies were altered.
As the mouse pregnancies were in a wildtype female, the disease
in these mice conﬁrms a fetoplacental origin of severe early-
onset pre-eclampsia caused in these mice by human STOX1 over-
expression.
SUSCEPTIBILITY GENE FOR THE HELLP-SYNDROME IS A LONG
NON-CODING RNA
The original Dutch study in families affected by severe pre-
eclampsia also consisted of families affected by the HELLP-
syndrome. Re-analysis of the original genome-wide scan per-
formed in these families led to the conclusion that in families
without the HELLP-syndrome (pre-eclampsia families) different
chromosomal linkage regions could be identiﬁed as were found
in the families with HELLP-syndrome (Lachmeijer et al., 2001).
This indicated that pre-eclampsia and the HELLP-syndrome are
different genetic entities. The chromosomal linkage associated
with the HELLP-syndrome has recently been found to be located
on chromosome 12q23 (Van Dijk et al., 2012). Here, a long
non-coding RNA (205 kb) has been identiﬁed that is expressed
in extravillous trophoblasts of ﬁrst trimester placenta. Further-
more, knockdown of this long non-coding RNA activated a
large set of genes involved in the cell cycle, associated with
a reduced activity of the G2/M phase while the G1/S phase
activity was increased, together suggesting a reduction in pro-
liferative activity of the cells. Finally, by blocking mutation
sites, as identiﬁed in children born out of HELLP pregnancies,
transcription of the non-coding RNA itself was upregulated caus-
ing a reduction in the amount of trophoblast cell invasion.
This would ﬁt the placental origin of the HELLP-syndrome in
which extravillous trophoblasts show reduced invasion into the
maternal decidua, caused by reduced differentiation of the extrav-
illous trophoblasts from a proliferative to an invasive phenotype,
already indicated by the cell cycle effects mediated by siRNA
knockdown.
CANDIDATE GENE APPROACHES IN PRE-ECLAMPSIA
Next to genetic screens also the candidate gene approach has been
used to detect genes associated with, primarily, pre-eclampsia.
These screens have largely focused on the maternal genotypes
involved and choose a single gene to investigate, based on bio-
logical function and thus potential involvement in the pathology
of pre-eclampsia. Pathways that have been under investigation
include pathways involved in oxidative stress, endothelial injury,
vasoactivity, coagulation, lipid metabolism, and inﬂammation.
The major problem with this type of research is again the dif-
ferences in patient populations used. Furthermore, because the
patients do not have a familial component, the number of patients
needed to identify susceptibility genes is much higher and there-
fore never reached to obtain reproducible results. The numbers
of genes that have been studied are too many to describe in this
review, but a recent meta-analysis identiﬁed seven genetic variants
to be consistently associated with pre-eclampsia (Buurma et al.,
2013). These were located in or near the genes ACE, CTLA4, F2,
FV (two variants), LPL, and SERPINE1. The functional signiﬁ-
cance of these variants in pre-eclampsia however yet needs to be
established.
Recently, a maternal pre-eclampsia susceptibility gene has been
described that inﬂuences trophoblast invasion and spiral artery
remodeling, i.e., CORIN (Cui et al., 2012). Corin is a cardiac
protease that activates atrial natriuretic peptide (ANP), a cardiac
hormone that is involved in blood pressure regulation. Corin- or
ANP-deﬁcient mice developed pre-eclampsia-like symptoms. Fur-
thermore, it was found that pre-eclamptic patients had reduced
uterine Corin levels. Finally, Corin gene mutations were identi-
ﬁed in pre-eclamptic patients leading to decreased corin activity.
How common mutations in this gene are in pre-eclamptic patients
remains to be investigated.
An interesting immunological fetal-maternal genetic interac-
tion should also be noted; HLA-C is a polymorphic gene expressed
by the invasive extravillous trophoblasts and a ligand for killer
immunoglobulin-like receptors (KIRs) that are expressed on the
maternal uterine natural killer cells (uNK). KIRs have two dif-
ferent alleles, A and B. It has been found that mothers that have
the AA KIR genotype while the fetus has HLA-C belonging to the
HLA-C2 group have an increased risk of developing pre-eclampsia
(Chazara et al., 2011).
EPIGENETICS OF PRE-ECLAMPSIA
EPIGENETICS
In genetics the term epigenetics is widely used these days to
describe heritable changes that are not caused by changes in the
underlying DNA sequence. The modiﬁcations mainly consist of
DNA methylation and histone modiﬁcations, both of which are
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able to regulate gene expression. These changes are heritable, i.e.,
they are maintained through multiple cell divisions.
A speciﬁc type of epigenetics is imprinting. During imprint-
ing only the allele inherited from mother or father is subject
to modiﬁcations to regulate gene expression. This has implica-
tions for the inheritance of disease; it will behave as an autosomal
dominant disease when inherited from the non-imprinted parent,
while it will be silent when inherited from the imprinted par-
ent. It becomes even more complicated when the concept of fetal
genotype determines maternal phenotype is introduced. In case
of a paternally imprinted, maternally expressed gene, the child
born from a phenotypically diseased pregnancy only needs to
have inherited the genotypically diseased allele from the mother
(being homozygous or heterozygous herself) to give the mother
symptoms during pregnancy. When the father is heterozygous
or homozygous for the diseased allele the pregnancy will not be
affected.
MATERNAL TRANSMISSION OF THE 10q22 CHROMOSOMAL REGION
The genome-wide scan using microsatellite markers in the Dutch
pre-eclampsia families already exposed a parent-of-origin effect;
only the maternal allele seemed to be involved in the linkage
observed (Oudejans et al., 2004). By sequencing the complete
linkage region on DNA of multiple generations, identifying
STOX1 Y153H, maternal transmission of the Y153H allele was
found (Van Dijk et al., 2005). However, no differential methy-
lation could be detected in the CpG island of the promoter
region of STOX1, the area predominantly affected by methy-
lation leading to differential expression (Van Dijk et al., 2007).
A second CpG island was identiﬁed in intron 1 of STOX1.
Methylation of this CpG island led to reduced expression con-
sistent with the normal association between hypermethylation
and downregulation of expression (Van Dijk et al., 2010). Fur-
thermore, in speciﬁc cell types, i.e., proliferating extravillous
trophoblasts, this region was subject to differential and allele-
speciﬁc methylation, where the methylated allele was paternal in
origin. Early placenta samples consisting of multiple cell types,
no allele-speciﬁc methylation could be detected, but an over-
all increase in methylation was seen in samples homozygous
for the STOX1 Y153H allele. As proliferating extravillous tro-
phoblasts are differentiated from villous cytotrophoblasts, it is
hypothesized that these cells are paternally imprinted as well.
In cell types where methylation is independent of parental ori-
gin, the Y153H genotype has the potential to direct the level of
methylation.
cdkn1c PRE-ECLAMPSIA MICE
CDKN1C is paternally imprinted in both humans and mice.
Pregnant mice heterozygous for cdkn1c deﬁciency (−/+) display
pre-eclampsia-like symptoms, i.e., hypertension and proteinuria.
This occurred in female −/+ mice that were mated with −/+
males or wildtype males, but not when wildtype females were
mated with −/+ males. The pregnant −/+ mice carried concep-
tuses with and without cdkn1c expression, only the conceptuses
without cdkn1c expression showed a lack of trophoblast invasion
and increase in trophoblast proliferation in the placenta, suggested
to cause the maternal symptoms (Kanayama et al., 2002). The
human CDKN1C gene does not show linkage with pre-eclampsia,
making its role in human pre-eclampsia unknown. However,
the importance of epigenetics in pregnancy-associated diseases
is clear.
FUTURE DIRECTIONS
Pregnancy-associated diseases with placental origin, especially
pre-eclampsia, are multi-factorial diseases in which both maternal
and fetoplacental factors are contributing, where different combi-
nations of factors will lead to differences in disease characteristics.
Some of these factors will be hereditary giving rise to the familial
component of the disease.
There is still a long way to go before the genetics of these
diseases are unraveled. This has a number of causes; the ﬁrst prob-
lem lies in the deﬁnition of different patient groups. As long as
patients (to identify maternal genes), and children born from dis-
eased pregnancies (to identify fetal genes), are not clearly deﬁned
and separated according to time of onset, placental morphology,
familial components, association with e.g., IUGR and associations
with maternal risk factors such as diabetes, cardiovascular disor-
ders, increased BMI, etc., it is almost impossible to identify the
susceptibility genes involved. Secondly, and this is especially the
case when investigating non-familial cases, the number of patients
needs to be extremely high to have enough power to identify
variations between patients and controls as the diseases are so
heterogeneous.
When more is known on the (epi)genetics of pregnancy-
associated diseases it will be easier to develop early non-invasive
diagnostic tests to be able to perform accurate risk proﬁling.
Preferably these tests are performed in maternal plasma, which
also contains fetal DNA and RNA, obtained in the ﬁrst trimester
of pregnancy before the onset of symptoms in the mother.
Using maternal plasma to detect fetal DNA and RNA is com-
plicated by the fact that 90–95% of the plasma consists of nucleic
acids of maternal origin. To be able to discriminate betweenmater-
nal and fetal DNA for epigenetic analysis it is therefore important
to only use chromosomal regions that are found to be either
highly methylated (>80%) or highly unmethylated (<20%) when
analyzed in plasma of non-pregnant women. Furthermore, to
properly discriminate between fetal and maternal DNA the dif-
ference in methylation levels between non-pregnant and pregnant
plasma should be at least 50%. When analyzing RNA expression
differences between pregnant patients and healthy pregnant con-
trols, the expression should preferably be completely absent in
non-pregnant plasma samples. Although the only cure currently
available is delivery of the baby, early diagnosis will increase mon-
itoring of women at risk and thereby decreasing morbidity and
mortality in both mother and child.
Unraveling the underlying (epi)genetic causes of pregnancy-
associated diseases with placental originwill not only yield options
for early diagnostics but will also gain fundamental insight into the
origin of disease, providing options for prevention and therapeutic
intervention.
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